Some have relabeled it as Pentadecapeptide Aringate or PDA (modifying the acetate to an arginate) and so are prescribing it for subcutaneous administration that way, while the confusion about its status has triggered a vibrant oral capsule market for BPC in what appears to get a gray area of legality. https://harryq876gur8.ltfblog.com/profile